2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Supportive Care, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Women’s Health, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

6136 Marstacimab prophylaxis in people living with severe hemophilia A with inhibitors: A phase III BASIS-anchored cost-effectiveness analysis

Kristina Rinaldi, Sam Hirniak, PhD2, Satoko Ito, MD, PhD3, Ding Quan Ng, PhD4, Manraj Sra, MD5, Margaret Lam, MD6, Robert Bona, MD7, Adam Cuker, MD, MS8, George Goshua, MD, SM9
1 Yale Cancer Center & Yale School of Medicine, New Haven, United States
2 Yale Cancer Center & Yale School of Medicine, New Haven, United States
3 Yale Cancer Center & Yale School of Medicine, New Haven, United States
4 Yale Cancer Center & Yale School of Medicine, New Haven, United States
5 Yale Cancer Center & Yale School of Medicine, New Haven, United States
6 Brown University, Providence, United States
7 Yale Cancer Center & Yale School of Medicine, New Haven, United States
8 University of Pennsylvania, Philadelphia, United States
9 Yale Cancer Center & Yale School of Medicine, New Haven, United States

*KR and SH are co-first authors

Introduction:
Hemophilia A (HA) is a rare inherited bleeding disorder characterized by factor VIII (FVIII) deficiency with ~30% of people with severe HA living with inhibitors. People with inhibitors experience frequent bleeding, progressive joint damage, impaired quality of life, and increased healthcare costs. Marstacimab, a once-weekly subcutaneous monoclonal antibody targeting tissue factor pathway inhibitor, demonstrated superior bleed prevention in the multinational phase 3 BASIS trial versus on-demand bypassing agent (BPA) in the care of people living with severe hemophilia with inhibitors, leading to Food and Drug Administration approval of marstacimab prophylaxis in the care of this population in the United States (US). However, the long-term economic value of marstacimab prophylaxis in people living with inhibitors remains unknown. We sought to fill this gap by conducting the first cost-effectiveness evaluation of marstacimab prophylaxis versus on-demand BPA treatment in the US.

Methods: We conducted an independent, non-industry-funded economic evaluation using a Markov cohort model to assess the lifetime cost-effectiveness of marstacimab prophylaxis compared with on-demand BPAs in people living with severe HA with inhibitors. Clinical efficacy inputs were derived from the inhibitor cohort of the multinational phase 3 BASIS trial. Breakthrough bleeds were managed with BPAs as follows: recombinant activated factor VII (rFVIIa) with eptacog alfa (Novoseven®) in the base case and eptacog beta (Sevenfact®) in scenario analysis. Costs were obtained from the Centers for Medicare & Medicaid Services and published literature. Health outcomes were measured in quality-adjusted life-years (QALYs) and quantified using BASIS trial-specific health-related quality-of-life outcomes. We internally validated our model by comparing model-predicted annual bleeding rates (ABRs) in both treatment arms with those observed in the BASIS trial. We conducted our analyses from the US healthcare system perspective. The primary outcome was the incremental net monetary benefit (iNMB) across all accepted willingness-to-pay (WTP) thresholds in the US, with the base-case reported at a recommended US WTP of $120,000/QALY. We concluded with deterministic sensitivity analysis to assess the influence of individual model parameters, and probabilistic sensitivity analysis to capture uncertainty in all parameters simultaneously over 10,000 Monte Carlo simulations.

Results: The projected ABRs were 1.02 with marstacimab prophylaxis (BASIS: 1.08) and 15.77 with on-demand BPA (BASIS: 18.99), respectively. In the base case, marstacimab prophylaxis and on-demand eptacog alfa accrued 16.54 and 12.10 discounted QALYs at discounted costs of $23.2 and $48.6 million. The per-patient iNMB of marstacimab prophylaxis was $25.9 million (95% credible interval: $15.1-39.3 million) in favor of marstacimab prophylaxis. In scenario analysis using eptacog beta, marstacimab prophylaxis and on-demand BPAs accrued 16.54 and 12.10 QALYs at discounted costs of $22.0 and $32.6 million, respectively, with an iNMB of $11.1 million (95% credible interval: $4.1-19.8 million) again in favor of marstacimab prophylaxis. One-way deterministic sensitivity analyses showed that drug price and rFVIIa dosing had the greatest impact on the results. In probabilistic sensitivity analysis, marstacimab was favored over on-demand treatment in 100% of 10,000 iterations.

Conclusion: These results indicate that marstacimab prophylaxis is cost-effective compared to on-demand treatment with either eptacog alfa or eptacog beta, for people living with HA with inhibitors. Marstacimab allows people living with hemophilia with inhibitors in the US to achieve greater quality-adjusted life-expectancy at lower lifetime costs than on-demand treatment. Adapting this model to each country across the multinational BASIS study would allow a global perspective.

Kristina Rinaldi: No relevant conflicts of interest to declare.